Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion.

Outside of the core registrational programs for these two important indications, we have several additional ongoing phase ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly (LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

On Aug. 7, 2025, Lilly reported Q2 earnings results that were 12.9% higher than the average estimate. That might seem to be ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by ...